SPHK1 and cancer: Early broad-spectrum inhibitors such as N, N-dimethyl-D-erythro-sphingosine (DMS) inhibit SphK1/2 activity competitively, blocking S1P production and inducing cancer cell apoptosis, but their lack of subtype specificity limits clinical application (42, 43).